CClinicalTrials.gg
CompletedNCT03606109Updated Sep 21, 2022Results posted

Reducing Hemarthrosis in Tibial Tubercle Osteotomy by the Administration of Intravenous Tranexamic Acid

A Phase 4 interventional study of Tranexamic Acid (TXA) in Tibial Tubercle Osteotomy, sponsored by NYU Langone Health. Completed at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-09-21.

Sponsored by NYU Langone Health · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
58
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

The purpose of the proposed study is to evaluate the effects of administering intravenous tranexamic acid (TXA) to patients undergoing high tibial osteotomy (HTO) and tibial tubercle osteotomy (TTO) to minimize hemarthrosis within the knee joint and post operative pain and swelling.

Read the detailed description

Not Provided

02

Conditions studied

  • Tibial Tubercle Osteotomy

Browse trials for

Keywords

  • Tibial Tubercle Osteotomy
  • Tranexamic Acid
03

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Patients undergoing TTO
  • Age 18-60
  • Willing and able to provide consent

Exclusion criteria

Exclusion Criteria:

  • Legally incompetent or mentally impaired (e.g., minors, Alzheimer's subjects, dementia, etc.)
  • Younger than 18 years of age
  • Older than 60 years of age
  • Any patient considered a vulnerable subject
  • Have bleeding or clotting disorder
  • Preoperative anticoagulation therapy
  • Abnormal coagulation profile
  • Renal disorder or insufficiency
  • Sickle cell disease
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
58 participants (actual)

Study arms

  • Active comparator
    High Tibial Osteotomy (HTO)

    Drug: Tranexamic Acid (TXA)

  • Active comparator
    Tibial Tubercle Ostetomy (TTO)

    Drug: Tranexamic Acid (TXA)

Interventions

  • DrugTranexamic Acid (TXA)

    One gram of intravenous tranexamic acid (TXA) will be administrated before tourniquet inflation and before closure of the incision, as 1 g has been shown to be a safe amount with minimal side effects

05

What researchers measure

Primary outcomes

  1. Perioperative Blood Loss

    Time frame: Perioperative, up to 2 hours

Secondary outcomes

  1. Score on Visual Analogue Scale (VAS) for Pain

    VAS will be used to report post-operative pain. A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.

    Time frame: Day 1

  2. Score on Visual Analogue Scale (VAS) for Pain

    VAS will be used to report post-operative pain. A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.

    Time frame: Day 4

  3. Score on Visual Analogue Scale (VAS) for Pain

    VAS will be used to report post-operative pain. A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.

    Time frame: Day 7

06

Results

Posted Sep 21, 2022

Participant flow

Participant flow — Overall Study
MilestoneHigh Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)
Started3127
Completed2926
Not completed21
Withdrew: Lost to follow-up21

Outcome measures

PrimaryPerioperative Blood Loss
Time frame:
Perioperative, up to 2 hours
Reported as:
Mean · mL
Perioperative Blood Loss
mLHigh Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)
Perioperative Blood Loss67.8 ± 56.5056.15 ± 33.92
SecondaryScore on Visual Analogue Scale (VAS) for Pain

VAS will be used to report post-operative pain. A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.

Time frame:
Day 1
Reported as:
Mean · score on a scale
Score on Visual Analogue Scale (VAS) for Pain
score on a scaleHigh Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)
Score on Visual Analogue Scale (VAS) for Pain7.13 ± 2.586.65 ± 2.66
SecondaryScore on Visual Analogue Scale (VAS) for Pain

VAS will be used to report post-operative pain. A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.

Time frame:
Day 4
Reported as:
Mean · score on a scale
Score on Visual Analogue Scale (VAS) for Pain
score on a scaleHigh Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)
Score on Visual Analogue Scale (VAS) for Pain5.82 ± 1.955.73 ± 2.26
SecondaryScore on Visual Analogue Scale (VAS) for Pain

VAS will be used to report post-operative pain. A patient is asked to indicate his/her perceived pain intensity (most commonly) along a 10 mm horizontal line, and this rating is then measured from the left edge (=VAS score). The total score range is 0 (no pain) to 10 (worst pain imaginable); the higher the score, the worse the pain.

Time frame:
Day 7
Reported as:
Mean · score on a scale
Score on Visual Analogue Scale (VAS) for Pain
score on a scaleHigh Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)
Score on Visual Analogue Scale (VAS) for Pain4.78 ± 1.764.77 ± 2.37

Adverse events

Collected over 1 year. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
High Tibial Osteotomy (HTO)0/31 (0%)0/31 (0%)0/31 (0%)
Tibial Tubercle Ostetomy (TTO)0/27 (0%)0/27 (0%)0/27 (0%)

Baseline characteristics

Age, Continuous
Age, Continuous(years)High Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)Total
Mean32.65 ± 8.8434.37 ± 8.0634.31 ± 8.93
Sex: Female, Male
Sex: Female, Male(Participants)High Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)Total
Female151328
Male141327
Race and Ethnicity Not Collected
Race and Ethnicity Not Collected(Participants)High Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)Total
Count of participants——0
Region of Enrollment
Region of Enrollment(participants)High Tibial Osteotomy (HTO)Tibial Tubercle Ostetomy (TTO)Total
United States292655
07

Study locations

1 site
  • New York University School of Medicine
    New York, New York 10016, United States
08

References and documents

Study documents

  • Protocol and statistical analysis plan · Jun 4, 2018

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03606109
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Jul 30, 2018
Start date
Jun 26, 2018
Primary completion
Jun 2, 2021
Completion
Jun 2, 2021
Results posted
Sep 21, 2022
Last update
Sep 21, 2022

Study contacts

Michael Alaia, MD
principal investigator · NYU Langone Health

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion